Serum omentin-1 level in patients with benign prostatic hyperplasia

Area of Science:

• Urology
• Endocrinology
• Biochemistry

Background:

• Benign prostatic hyperplasia (BPH) is a prevalent urological condition in aging men.
• Lower serum omentin-1 levels correlate with conditions implicated in BPH pathogenesis, such as inflammation, diabetes, and obesity.
• The specific relationship between omentin-1 and BPH remains under-investigated.

Purpose of the Study:

• To investigate the association between serum omentin-1 levels and benign prostatic hyperplasia (BPH).
• To explore the correlation of omentin-1 with anthropometric and biochemical parameters in BPH patients.
• To examine the relationship between omentin-1 and the expression of inflammatory markers IL-8 and IL-18 in BPH.

Main Methods:

• Study included 70 males: 40 with BPH and 30 healthy controls.
• Measured anthropometric and biochemical parameters, including serum omentin-1 levels.
• Assessed mRNA expression of IL-8 and IL-18 in prostate tissues from BPH patients.

Main Results:

• Serum omentin-1 levels were significantly lower in BPH patients compared to controls (p < 0.001).
• A negative correlation was observed between serum omentin-1 and Body Mass Index (BMI) in both BPH and overall groups (p < 0.013).
• Lower omentin-1 levels were associated with increased IL-8 and IL-18 mRNA expression in BPH tissues.

Conclusions:

• Omentin-1 may play a suppressive role in the development of benign prostatic hyperplasia.
• Reduced serum omentin-1 levels in BPH patients may correlate with increased prostate volume and elevated IL-8/IL-18 expression.